DES (Diethylstilbestrol) Info

DES (Diethylstilbestrol) Info We welcome everyone from the DES community -- Mothers, Daughters, Sons, 3rd Generation and all exposed! In some clinics, it was given to every pregnant patient.

DES Info Association:

The DES tragedy of in-utero exposure and its devastating effects on multiple generations must not be forgotten. The medical community need education about the sequela of DES Exposure. (1) know how to screen the DES exposed, (2) Know the continueing long term effects of DES exposure, and (3) Provide prompt care when DES Exposed patients develop complications.

** What is DES (diethylstilbestrol)? **

DES (diethylstilbestrol), is a teratogenic and carcinogenic synthetic estrogen (Endocrine Disruptor) , is the world’s first major drug disaster. It was prescribed to millions of pregnant women for decades: from 1938 into the 1970s in the United States; and until the mid-1980s in parts of Latin America, Europe, Australia, and the Third World (Currently in Kenya). The currently proven effects of exposure include a rare vaginal cancer in DES Daughters; greater risk for breast cancer in DES Mothers; possible risk for testicular cancer in DES Sons, along with transgender and reproductive malformations; abnormal reproductive organs; infertility; high-risk pregnancies; Skeletal issues and an increased risk for breast cancer in DES Daughters. There are a number of other suspected effects, including auto-immune disorders, but many of these effects are still awaiting further research. For decades, Big Pharma claimed DES prevented miscarriages and problem pregnancies. It was sometimes given as an injection, but primarily it was prescribed in pill form. Never patented, DES was marketed under 200 different names, although the majority of the drug was actually produced by Eli Lilly. DES was sometimes even included in prescription prenatal vitamins. As early as 1938, studies showed that DES promoted cancer in lab animals. But at that time, people thought animal studies only provided a hint of what could happen in humans. Also, no one knew that drugs could cross the placenta and affect a baby in utero. (Note there was a 1941 mouse study that showed mice with absent or deformed fallopian tubes. The warning signs were there for humans.) In 1941, the original clinical uses for DES were to treat gonorrheal vaginitis, senile vaginitis, menopausal symptoms and to suppress lactation. Between 1941 and 1947, it was used for pregnancy without FDA approval. No controlled studies were ever conducted by the drug companies to determine the effectiveness or safety of DES for use during pregnancy, even after some scientists started questioning its efficacy in the 1950s. As early as 1953, research revealed that DES did not work (The Dieckmann Study) – that DES actually brought about higher rates of premature birth and infant mortality – yet DES continued to be prescribed to pregnant women for decades. This is because pharmaceutical companies continued to heavily promote DES use to doctors. The drug was a top moneymaker for Big Pharma. In the late 1960s, there was an unprecedented appearance of rare cancer in young women. Clear cell cancer (CCA) – a rare cancer of the vagina – was diagnosed in an age group never before found to develop it. (Normally elderly women developed CCA.) There were eight such cases at Massachusetts General Hospital in Boston alone. One of the mothers raised the question of whether her daughter's cancer might be connected to DES exposure in utero. Doctors discovered the DES link in 1971 and published their findings in the April 1971 issue of New England Journal of Medicine. News of the cancer cases made national headlines. However, the FDA did not act on this information until public pressure, including Congressional Hearings, forced the FDA to issue a warning about DES in November 1971. The drug was not banned for human use. DES was contraindicated for pregnancy by the FDA in 1972. It was not until September 2000 that the FDA finally withdrew its approval of DES for humans. Researchers are now investigating whether DES health issues are extending into the next generation, the so-called DES Grandchildren (Third Generation). As study results come in, there is growing evidence that this group has been adversely impacted by a drug prescribed to their grandmothers. To this day, not one drug company has ever apologized or accepted responsibility for the DES tragedy. Nevertheless, they have paid millions in out-of-court settlements and verdicts to DES Daughters and Sons who suffered injuries from their exposure. Please join us in our mission to continue to provide information to the DES exposed on DES information and other health related information along with pushing for more physician education to know how to care for the DES exposed. Also, we are continuing to push for more research! Our moto is "Knowledge is Power" DES Info Association is a free resource for Diethylstilbestrol Information and Research

“DISCLAIMER: THIS SITE DOES NOT PROVIDE MEDICAL ADVICE. The information on this site, including but not limited to text, graphics, images and other material, is for informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. If you have any questions about how the information contained on this website may relate to you, you should seek the advice of a physician or other qualified health care professional.”

DES Info: DES Exposure and link to cardiac structure and function.Haddad R, Kasneci A, Sebag IA, Chalifour LE. “Cardiac ...
04/17/2026

DES Info: DES Exposure and link to cardiac structure and function.

Haddad R, Kasneci A, Sebag IA, Chalifour LE. “Cardiac structure/function, protein expression, and DNA methylation are changed in adult female mice exposed to diethylstilbestrol in utero.” Can J Physiol Pharmacol. 2013 Sep;91(9):741-9. doi: 10.1139/cjpp-2013-0014. Epub 2013 Apr 24. PMID: 23984849.

This is an important research article and concludes with the following: “However, DES-treated mice had increased DNA methylation in the calsequestrin 2 promoter. Thus, gestational exposure to DES altered female ventricular DNA, cardiac structure/function, and calcium homeostasis protein expression. We conclude that gestational exposure to estrogenizing compounds may impact cardiac structure/function in adult females.”

https://pubmed.ncbi.nlm.nih.gov/23984849/

For further information, please review the article online or contact DES Info Association at DESInfo411@gmail.com. Please include the title of the article.



DESInfo411@gmail.com

The detrimental effects of in utero exposure to the non-steroidal estrogen diethylstilbestrol (DES) are particularly marked in women. Fetal hearts express estrogen receptors, making them potentially responsive to DES. To examine whether gestational exposure to DES would impact the heart, we exposed....

DES Info: DES patient with a very late recurrence of cancerAdani-Ifè A, Goldschmidt E, Innominato P, Ulusakarya A, Errih...
04/16/2026

DES Info: DES patient with a very late recurrence of cancer

Adani-Ifè A, Goldschmidt E, Innominato P, Ulusakarya A, Errihani H, Bertheau P, Morère JF. “Very late recurrence of Diethylstilbestrol - related clear cell carcinoma of the cervix: case report.” Gynecol Oncol Res Pract. 2015 Jul 17;2:3. doi: 10.1186/s40661-015-0010-5. PMID: 27231563; PMCID: PMC4880817.

This reports concludes with the following:
“To summarize, this case represents the longest reported disease-free interval till recurrence and the first description of metastatic liver disease of DES related clear cell adenocarcinoma of the cervix.”
“It reemphasizes the necessity of long-term surveillance of DES exposed women and confirms previous reports recommending the importance of frequent follow-up examination not only of the pelvis but also of all distant potential sites of metastasis.”

https://pmc.ncbi.nlm.nih.gov/articles/PMC4880817/

For further information, please review the article online or contact DES Info Association at DESInfo411@gmail.com. Please include the title of the article.


DESInfo411@gmail.com

Clear cell adenocarcinoma of the cervix is a rare tumor of the lower ge***al tract. It has been described in young women with a history of intra uterine exposure to diethylstilbestrol. This tumor is characterized by a greater tendency for late ...

DES Info: DES - Primary Non-Clear-Cell Adenocarcinoma of the Va**na .Patel, Samit A., and Jan Sunde. "Primary non-clear-...
04/14/2026

DES Info: DES - Primary Non-Clear-Cell Adenocarcinoma of the Va**na .

Patel, Samit A., and Jan Sunde. "Primary non-clear-cell adenocarcinoma of the va**na in a diethylstilbestrol exposed woman." Military Medicine 179.4 (2014): e461-e462.

"This study concludes with the following “Reports of non-clear-cell adenocarcinoma of the va**na following DES are rare. It is known that young women exposed prenatally to DES are affected by reproductive tract abnormalities and also have an increased risk of CCA.”

“There have been reports of health risks in groups of DES-exposed women, which suggest possible effects or cancers at a later age.”
“Women exposed to DES in-utero should have continued monitoring for cervical and va**nal lesions.”

DES Info: We have been told that DES was heavily prescribed to women being cared for my military physicians.
https://pubmed.ncbi.nlm.nih.gov/24690973/

For further information, please review the article online or contact DES Info Association at DESInfo411@gmail.com. Please include the title of the article.



DESInfo411@gmail.com

A 54-year-old woman with a history of in-utero diethylstilbestrol (DES) exposure, who had a prior hysterectomy for symptomatic leiomyomata and dysmenorrhea, presented for va**nal bleeding. Va**nal biopsies showed a non-clear-cell adenocarcinoma, and the patient was subsequently treated with radiatio...

Thanks for being a top engager and making it on to my weekly engagement list! 🎉 Jude Denzer, Martha A Russell, Mariana M...
04/14/2026

Thanks for being a top engager and making it on to my weekly engagement list! 🎉 Jude Denzer, Martha A Russell, Mariana Moculescu, Ian Cameron-Fleming, Dawn Gundlach

DES Info: DES and stem cell damageHabas, Khaled, Martin H. Brinkworth, and Diana Anderson. "Diethylstilbestrol induces o...
04/13/2026

DES Info: DES and stem cell damage

Habas, Khaled, Martin H. Brinkworth, and Diana Anderson. "Diethylstilbestrol induces oxidative DNA damage, resulting in apoptosis of spermatogonial stem cells in vitro." Toxicology 382 (2017): 117-121.

This study concludes with the following: “The results showed DES-induced DNA damage, increased apoptotic cells, and increased production of intracellular superoxide anions. Investigating the mechanisms and biology of SSCs in this way helps to provide a better understanding of spermatogonial stem cell regulation.”

https://pubmed.ncbi.nlm.nih.gov/28315349/

For further information, please review the article online or contact DES Info Association at DESInfo411@gmail.com. Please include the title of the article.



DESINfo411@gmail.com

The spermatogonial stem cells (SSCs) are the only germline stem cells in adults that are responsible for the transmission of genetic information from mammals to the next generation. SSCs play a very important role in the maintenance of progression of spermatogenesis and help provide an understanding...

DES Info: Olive Smith’s Paper on DES 1948SMITH OW. “Diethylstilbestrol in the prevention and treatment of complications ...
04/10/2026

DES Info: Olive Smith’s Paper on DES 1948

SMITH OW. “Diethylstilbestrol in the prevention and treatment of complications of pregnancy. “Am J Obstet Gynecol. 1948 Nov;56(5):821-34. PMID: 18888213.

This is an important article especially given her conclusion: “Smith concludes that DES is an effective treatment for pregnancy complication and risk of early miscarriage. She states that DES should not be used to treat symptoms later in the pregnancy and that administration with DES must start early in the pregnancy.”
DES Info: The DES Tragedy had begun and continues today. Multiple generations are affected!

https://pubmed.ncbi.nlm.nih.gov/18888213/

For further information, please review the article online or contact DES Info Association at DESInfo411@gmail.com. Please include the title of the article.



DESInfo411@gmail.com

Big thanks to Mariana Moculescu, Paula Smithfor all your support! Congrats for being top fans on a streak 🔥!
03/28/2026

Big thanks to Mariana Moculescu, Paula Smith

for all your support! Congrats for being top fans on a streak 🔥!

DES Info: DES causes Upper ge***al tract changes in the DES ExposedKaufman RH, Adam E, Binder GL, Gerthoffer E. “Upper g...
03/28/2026

DES Info: DES causes Upper ge***al tract changes in the DES Exposed

Kaufman RH, Adam E, Binder GL, Gerthoffer E. “Upper ge***al tract changes and pregnancy outcome in offspring exposed in utero to diethylstilbestrol.” Am J Obstet Gynecol. 1980 Jun 1;137(3):299-308. doi: 10.1016/0002-9378(80)90913-8. PMID: 7377249.

This was an important study that showed: “The women with abnormal x-ray films had more ectopic pregnancies, spontaneous abortions, and premature deliveries than women with normal x-ray films although these differences were not statistically significant. Significantly fewer women with abnormal findings than women with normal x-rays were delivered of term infants.”

https://pubmed.ncbi.nlm.nih.gov/7377249/

For further information, please review the article online or contact DES Info Association at DESInfo411@gmail.com. Please include the title of the article in your request



DESInfo411@gmail.com

Hysterosalpingography (HSG) was performed on 267 diethylstilbestrol (DES)-exposed women. One hundred eighty-five (69%) of these women demonstrated an abnormality and 82 women had normal findings. A relationship between abnormal x-ray findings and structural abnormalities of the cervix and va**nal ep...

DES Info: FDA Drug Bulletin November 1971 (DES Not Banned – DES Contraindicated)Diethylstilbestrol Contraindicated in Pr...
03/26/2026

DES Info: FDA Drug Bulletin November 1971 (DES Not Banned – DES Contraindicated)

Diethylstilbestrol Contraindicated in Pregnancy: Drug's Use Linked to Adenocarcinoma in the Offspring WE WISH TO BRING to the attention of all physicians, hospitals, and medical personnel an important possible toxic effect of diethylstilbestrol (DES) reported for the first time in April 1971 by Herbst et al.1

From their studies the authors concluded that maternal ingestion of diethylstilbestrol during pregnancy appears to increase the risk of va**nal adenocarcinoma developing years later in the offspring exposed.

The authors studied eight cases of adenocarcinoma of the va**na in patients born between 1946 and 1951. The malignancies were identified and treated between 1966 and 1969. In seven of the eight cases, there was a history -of maternal use of diethylstilbestrol. Because this type of malignancy in young girls had rarely been reported previously, the authors conducted a retrospective investigation in an attempt to find factors that may be associated with such malignancy in this age group. Four matched controls were established for each patient and the data obtained were subjected to statistical analysis.

A statistically significant relationship was observed for three variables: diethylstilbestrol given during pregnancy (p=.00001), bleeding in that pregnancy (p=less than .05) and prior pregnancy loss (p=less than .01).

It is obvious that the most significant of the variables is the administration of diethylstilbestrol during pregnancy. Since publication of this study, five additional cases of this malignancy associated with the maternal use of diethylstilbestrol have been reported by Greenwald et al.2

Dr. Herbst, in a recent communication to FDA, has reported an additional 15 cases associated with use of this drug, bringing the total number of known cases to 27. It must be emphasized that this type of epidemiologic study defines only an association and not necessarily a cause-and-effect relationship.

Further studies are underway to clarify the significance of these findings. In the meantime, the FDA is initiating the following precautionary actions:

1. All manufacturers of DES or closely related congeners (dienestrol, hexestrol, benzestrol, promethestrol) are being notified that appropriate changes will be required in the labeling for such drugs. This change will consist in the listing of pregnancy as a contraindication to the use of diethylstilbestrol and the other above-mentioned compounds.

2. All other estrogens will be required to have the following WARNING in their labeling: "A statistically significant association has been reported between maternal ingestion during pregnancy of diethylstilbestrol and the occurrence of va**nal carcinoma developing years later in the offspring. Whether such an association is applicable to all estrogens is not known at this time. In any event, estrogens are not indicated for use during pregnancy."

3. Epidemiological studies are being initiated to determine the true incidence of this disease in young women, the number at risk, the characteristics of patient populations with this malignancy, and the probability of a cause-and-effect relationship.

Both FDA and the medical profession face a responsibility to help determine whether this reported association constitutes a cause-and-effect relationship. We ask that all physicians consider appropriate steps to assist FDA casefinding and to protect any patients who might be at risk.

It may be possible to trace the offspring of those mothers who received DES during pregnancy.

All physicians should be especially' alert for young women whose mothers may have received hormonal therapy during pregnancy, particularly those young women who may be experiencing irregular va**nal bleeding. The association should be a routine consideration for physicians whose practice includes young women.

This is a previously unsuspected health problem. Further information is essential to the FDA and to the medical profession. We ask your help in reporting any cases you encounter for entry in a case registry. FDA will take every possible step to ensure that you are kept abreast of new information as soon as it can be gathered and analyzed.

REFERENCES
1. Herbst AL, Ulfelder H, Poskanzer DC: Adenocarcinoma of the va**na: Association of-- maternal stilbestrol therapy with tumor appearance in young women. New Engl j Med 284:878-881, Apr 22, 1971
2. Greenwald P, Barlow JJ, Nasca PC, et al: Va**nal cancer, after maternal treatment with synthetic estrogens. New Engl J Med 285: 390-392, Aug 12, 1971



DESInfo411@gmail.com

DES Info: DES discovery and article published in 1938 by E.C. Dodds. DODDS, E., GOLDBERG, L., LAWSON, W. et al. “OEstrog...
03/25/2026

DES Info: DES discovery and article published in 1938 by E.C. Dodds.

DODDS, E., GOLDBERG, L., LAWSON, W. et al. “OEstrogenic Activity of Certain Synthetic Compounds.” Nature 141, 247–248 (1938). https://doi.org/10.1038/141247b0

The start of The DES Tragedy…:

In certain directions, especially in the diphenylethane and stilbene groups, we found it convenient to join forces in order to avoid duplication of work.:

The beginning discovery and elements of The DES Tragedy
For further information, please review the article online or contact DES Info Association at DESInfo411@gmail.com. Please include the title of the article.



DESInfo411@gmail.com

DES Info: DES and Brittle Bones.Migliaccio S, Newbold RR, Bullock BC, Jefferson WJ, Sutton FG Jr, McLachlan JA, Korach K...
03/24/2026

DES Info: DES and Brittle Bones.

Migliaccio S, Newbold RR, Bullock BC, Jefferson WJ, Sutton FG Jr, McLachlan JA, Korach KS. “Alterations of maternal estrogen levels during gestation affect the skeleton of female offspring.” Endocrinology. 1996 May;137(5):2118-25. doi: 10.1210/endo.137.5.8612556. PMID: 8612556.
Alterations of maternal estrogen levels during gestation affect the skeleton of female offspring

https://pubmed.ncbi.nlm.nih.gov/8612556/

This is an important study. The study concludes with the following: “In summary, these data show, for the first time, that alterations in the maternal estrogenic levels during pregnancy can influence early phases of fetal bone tissue development and subsequently result in permanent changes in the skeleton. Finally, the effect of this short-term estrogen treatment can be seen in the fetal skeleton, suggesting an estrogen-imprinting effect on bone cell-programming in fetal life because treatment effects on bone cell turnover can be observed later in adult life.”



DESInfo411@gmail.com

Estrogens have important effects on bone turnover in both humans and experimental animals models. Moreover, the decreased level of estrogen after menopause appears to be one of the key factors in determining postmenopausal osteoporosis. The presence of estrogen receptor in both osteoblasts and osteo...

Address

Dallas, TX

Telephone

+19728208400

Website

https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/des-fact-sheet,

Alerts

Be the first to know and let us send you an email when DES (Diethylstilbestrol) Info posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to DES (Diethylstilbestrol) Info:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram